{"id":822240,"date":"2025-03-05T17:18:30","date_gmt":"2025-03-05T22:18:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/"},"modified":"2025-03-05T17:18:30","modified_gmt":"2025-03-05T22:18:30","slug":"lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/","title":{"rendered":"Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NEW YORK<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 5, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0<b><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4376956-1&amp;h=3517357016&amp;u=https%3A%2F%2Fwww.luciddx.com%2F&amp;a=Lucid+Diagnostics+Inc.\" target=\"_blank\" rel=\"nofollow\">Lucid Diagnostics Inc.<\/a><\/b>\u00a0(Nasdaq: LUCD)\u00a0(&#8220;Lucid&#8221; or the &#8220;Company&#8221;), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced registered direct offering of 13,939,331 shares of common stock at a purchase price of <span class=\"xn-money\">$1.10<\/span> per share. \u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2003008\/Lucid_TM_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2003008\/Lucid_TM_Logo.jpg\" title=\"Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer \u2013 the EsoGuard\u00ae Esophageal DNA Test and EsoCheck\u00ae Esophageal Cell Collection Device. (PRNewsfoto\/Lucid Diagnostics)\" alt=\"Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer \u2013 the EsoGuard\u00ae Esophageal DNA Test and EsoCheck\u00ae Esophageal Cell Collection Device. (PRNewsfoto\/Lucid Diagnostics)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>The gross proceeds to the Company from this offering are approximately <span class=\"xn-money\">$15.3 million<\/span>, before deducting the approximately <span class=\"xn-money\">$0.8 million<\/span> in placement agent&#8217;s fees and other offering expenses payable by the Company. Canaccord Genuity acted as the sole placement agent for this offering.<\/p>\n<p>The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes.<\/p>\n<p>The securities described above were offered pursuant to a registration statement on Form S-3 (File No. 333-268560), which was declared effective by the Securities and Exchange Commission on <span class=\"xn-chron\">December 6, 2022<\/span>. A final prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC&#8217;s website at\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4376956-1&amp;h=2805288528&amp;u=http%3A%2F%2Fwww.sec.gov%2F&amp;a=http%3A%2F%2Fwww.sec.gov\" target=\"_blank\" rel=\"nofollow\">http:\/\/www.sec.gov<\/a>. Electronic copies of the final prospectus supplement and accompanying base prospectus included in the registration statement may be obtained by contacting Canaccord Genuity LLC, Attention: Syndicate Department, <span class=\"xn-person\">One Post Office Square<\/span>, Suite 3000, <span class=\"xn-location\">Boston, MA<\/span> 02109, or by email at\u00a0<a href=\"mailto:prospectus@cgf.com\" target=\"_blank\" rel=\"nofollow\">prospectus@cgf.com<\/a>.<\/p>\n<p>\n        <b>About Lucid Diagnostics<br \/><\/b>Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid&#8217;s <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4376956-1&amp;h=440282945&amp;u=http%3A%2F%2Fwww.esoguard.com%2F&amp;a=EsoGuard%C2%AE+Esophageal+DNA+Test\" target=\"_blank\" rel=\"nofollow\">EsoGuard<sup>\u00ae<\/sup> Esophageal DNA Test<\/a>, performed on samples collected in a brief, noninvasive office procedure with its <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4376956-1&amp;h=1602166715&amp;u=https%3A%2F%2Fwww.luciddx.com%2Fprecancer-detection%2Fesocheck&amp;a=EsoCheck%C2%AE+Esophageal+Cell+Collection+Device\" target=\"_blank\" rel=\"nofollow\">EsoCheck<sup>\u00ae<\/sup> Esophageal Cell Collection Device<\/a>, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.<\/p>\n<p>For more information about Lucid, please visit <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4376956-1&amp;h=1681623391&amp;u=http%3A%2F%2Fwww.luciddx.com%2F&amp;a=www.luciddx.com\" target=\"_blank\" rel=\"nofollow\">www.luciddx.com<\/a> and for more information about its parent company PAVmed, please visit <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4376956-1&amp;h=3422442072&amp;u=http%3A%2F%2Fwww.pavmed.com%2F&amp;a=www.pavmed.com\" target=\"_blank\" rel=\"nofollow\">www.pavmed.com<\/a>.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY34480&amp;sd=2025-03-05\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering-302393766.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering-302393766.html<\/a><\/p>\n<p>SOURCE  Lucid Diagnostics<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY34480&amp;Transmission_Id=202503051645PR_NEWS_USPR_____NY34480&amp;DateId=20250305\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK , March 5, 2025 \/PRNewswire\/ &#8212;\u00a0Lucid Diagnostics Inc.\u00a0(Nasdaq: LUCD)\u00a0(&#8220;Lucid&#8221; or the &#8220;Company&#8221;), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced registered direct offering of 13,939,331 shares of common stock at a purchase price of $1.10 per share. \u00a0 The gross proceeds to the Company from this offering are approximately $15.3 million, before deducting the approximately $0.8 million in placement agent&#8217;s fees and other offering expenses payable by the Company. Canaccord Genuity acted as the sole placement agent for this offering. The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes. The securities described &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-822240","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , March 5, 2025 \/PRNewswire\/ &#8212;\u00a0Lucid Diagnostics Inc.\u00a0(Nasdaq: LUCD)\u00a0(&#8220;Lucid&#8221; or the &#8220;Company&#8221;), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced registered direct offering of 13,939,331 shares of common stock at a purchase price of $1.10 per share. \u00a0 The gross proceeds to the Company from this offering are approximately $15.3 million, before deducting the approximately $0.8 million in placement agent&#8217;s fees and other offering expenses payable by the Company. Canaccord Genuity acted as the sole placement agent for this offering. The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes. The securities described &hellip; Continue reading &quot;Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-05T22:18:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2003008\/Lucid_TM_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering\",\"datePublished\":\"2025-03-05T22:18:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\\\/\"},\"wordCount\":358,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2003008\\\/Lucid_TM_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\\\/\",\"name\":\"Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2003008\\\/Lucid_TM_Logo.jpg\",\"datePublished\":\"2025-03-05T22:18:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2003008\\\/Lucid_TM_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2003008\\\/Lucid_TM_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/","og_locale":"en_US","og_type":"article","og_title":"Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering - Market Newsdesk","og_description":"PR Newswire NEW YORK , March 5, 2025 \/PRNewswire\/ &#8212;\u00a0Lucid Diagnostics Inc.\u00a0(Nasdaq: LUCD)\u00a0(&#8220;Lucid&#8221; or the &#8220;Company&#8221;), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced registered direct offering of 13,939,331 shares of common stock at a purchase price of $1.10 per share. \u00a0 The gross proceeds to the Company from this offering are approximately $15.3 million, before deducting the approximately $0.8 million in placement agent&#8217;s fees and other offering expenses payable by the Company. Canaccord Genuity acted as the sole placement agent for this offering. The Company intends to use the net proceeds from this offering for working capital and other general corporate purposes. The securities described &hellip; Continue reading \"Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-05T22:18:30+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2003008\/Lucid_TM_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering","datePublished":"2025-03-05T22:18:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/"},"wordCount":358,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2003008\/Lucid_TM_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/","name":"Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2003008\/Lucid_TM_Logo.jpg","datePublished":"2025-03-05T22:18:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2003008\/Lucid_TM_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2003008\/Lucid_TM_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-announces-closing-of-15-3-million-registered-direct-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/822240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=822240"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/822240\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=822240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=822240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=822240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}